Contineum Therapeutics (CTNM) 45th Annual Global Healthcare Conference summary

Company overview and strategy

• Focuses on neuroscience, inflammation, and immunology, targeting unmet medical needs with internally derived assets.

• Two clinical-stage assets: PIPE-791 (LPA1 inhibitor) and PIPE-307 (M1 receptor antagonist), each advancing in multiple indications.

• PIPE-791 targets progressive MS and idiopathic pulmonary fibrosis (IPF), with phase 2 trials planned for 2025.

• PIPE-307 is a CNS-focused program with a collaboration established with Johnson & Johnson.

• Early de-risking through clinical validation and receptor occupancy studies.

PIPE-791: Mechanism, differentiation, and clinical plans

• Inhibits LPA1 to address remyelination and neuroinflammation in progressive MS; also being developed for IPF.

• Preclinical models show translatable benefits in remyelination, with visual evoked potential latency as a key measure.

• Phase 2 trials in 2025 will assess remyelination (VEP, low contrast letter acuity, neurofilament light) and neuroinflammation (MRI, PET imaging).

• Differentiated from other LPA1 antagonists by once-daily low-dose regimen, high receptor occupancy, and favorable pharmacokinetics.

• Chronic tox studies ongoing; PET ligand studies in healthy volunteers and patients to further validate receptor occupancy.

PIPE-307: Collaboration, selectivity, and clinical progress

• Selective M1 receptor antagonist designed to avoid cognitive side effects seen with non-selective anti-muscarinics.

• Healthy volunteer studies showed no cognitive impairment at any dose or time point.

• Collaboration with J&J driven by preclinical and clinical validation of remyelination and rapid antidepressant effects.

• Phase 2 VISTA trial in RRMS is enrolling well, targeting around 160 subjects.

• Low contrast letter acuity and VEP are key endpoints; 5-7 letter improvement considered clinically meaningful.